immuno-oncology

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead

Lucid Diligence Brief: Sprint Bioscience sells TREX1 program to Gilead…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe

Lucid Diligence Brief: Vaximm VXM01 License Term Sheet with BCM Europe…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: ModeX Therapeutics and Regeneron collaboration

Lucid Diligence Brief: ModeX Therapeutics and Regeneron collaboration…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Takeda and Innovent global oncology partnership

Lucid Diligence Brief: Takeda and Innovent global oncology partnership…

by Timos Papagatsias

Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics

Lucid Diligence Brief: Ipsen to acquire ImCheck Therapeutics Professional…

by Timos Papagatsias

Onco_background

Oncology Weekly News - September 22nd 2025

Oncology Update: RGT-61159 Orphan Drug, CRB-701 Fast Track, PDS0101 Survival…

by LucidQuest

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required
You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.